We intend to focus on businesses primarily operating in the life sciences sector. (Incorporated in the Cayman Islands) 

We will focus on companies that use cutting edge technologies such as artificial intelligence, mechanistic genetics, or structure-based drug design, to reduce development time and increase the probability of success.

Our management team will be led by our CEO, Dr. Someit Sidhu, who has successfully identified R&D stage compounds and subsequently in-licensed and/or developed those compounds through critical value-creating milestones leading to several successful exits. This includes  companies such as Izana Bioscience and Akaza Bioscience for each of which Dr. Sidhu served as co-founder and CEO. He is also the co-founder of Pathios Therapeutics.

Our COO, Dr. Tauhid Ali, launched three companies out of Takeda’s TAKcelerator™, which he founded and ran at Takeda Pharmaceuticals.

We believe that the combined expertise and deep relationships of our management and board provide us unique access and insight to research and development stage assets whether independently housed in private companies, in development within leading academic institutions, or embedded in large-cap pharma.

(Note: Five qualified institutional buyers and an accredited investor, collectively referred to as the “anchor investors” throughout this prospectus, expressed to us their several interests in purchasing up to $81.4 million of units in this offering.)

(Note: JATT Acquisition priced its SPAC IPO on July 13, 2021, in line with the terms in its prospectus: 12 million units at $10 each to raise $120 million.)